LAS VEGAS, NV--(Marketwired - May 11, 2015) - Alkame Holdings, Inc. (
Haggen, the 82 -year-old-grocer based in Washington State has been described as Whole Foods meets Safeway, acquired stores in the Albertsons-Safeway merger and is converting them into Haggen stores. Market share has grown roughly nine fold to a total of 164 stores and quintupling its employee size from 2,000 to 10,000. Albertsons and Safeway, whose merger was announced last March, were required by the Federal Trade Commission to divest 168 stores so the combined company didn't create unfair control of the retail market.
Alkame Holdings, Inc. CEO, Robert Eakle stated, "Southern California is a wonderful market for us. We continue to see great enthusiasm and movement of our product. We are glad to be a part of Haggens expansion plans into the California marketplace. Our product is gaining wonderful penetration thanks to our DSD distribution partner Avanzar Sales & Distribution, who is majority owned by Minerco Resources Inc. (
About Alkame Holdings, Inc. (ALKM)
Alkame Holdings, Inc. is a publicly traded health and technology holding company with a focus on patentable, innovative, and eco-friendly consumer products. The Company's wholly-owned subsidiary, Alkame Water, Inc., markets and distributes micro-clustered, alkaline, antioxidant and oxygenated bottled water utilizing an exclusive patented formula and technology. Alkame uses this patented technology to create water with several unique properties which allow the body to absorb and utilize it more efficiently and help to achieve an optimal pH balance. This patented technology also increases the available oxygen content and absorbability which equates to more fuel for improved metabolic efficiency, boosted immune system, and improved cardio respiratory function.
For more information visit: www.alkameholdingsinc.com
Disclaimer/Safe Harbor: This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that Alkame will achieve significant sales, the failure to meet schedule or performance requirements of the Company's contracts, the Company's liquidity position, the Company's ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.